University of Alberta, Edmonton, Alberta, Canada.
Duke University, Durham, North Carolina.
Arthritis Care Res (Hoboken). 2021 Jul;73(7):940-946. doi: 10.1002/acr.24537.
To describe characteristics of children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA) who were enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry.
All children with ERA and those with juvenile PsA were identified. Demographic characteristics, clinical characteristics, and treatments were described. The children with sacroiliitis and those without sacroiliitis were compared. In the children with sacroiliitis, the first visit with clinically active sacroiliitis (which came first in 72% of cases) was compared to the first visit without clinically active sacroiliitis.
A total of 902 children with ERA or juvenile PsA were identified. Children with ERA were older at diagnosis (ages 10.8 years versus 8.2 years; P < 0.01) and were more likely to be male (56% versus 38%; P < 0.01). Polyarticular involvement was reported in 57% of children with ERA and in 72% of those with juvenile PsA. Of the children tested, HLA-B27 was positive in 38% of those in the ERA group and in 12% of those in the juvenile PsA group. At least 1 biologic was taken by 72% of those with ERA and 64% of those with juvenile PsA. Sacroiliitis (diagnosed clinically and/or by imaging) was reported in 28% of the children (40% of those with ERA and 12% of those with juvenile PsA). Of these, 54% of the children were female, 36% were HLA-B27 positive, and 81% took at least 1 biologic. In children with sacroiliitis, scores according to the physician global assessment of disease activity, parent/patient global assessment of well-being, and clinical Juvenile Arthritis Disease Activity Score 10 were all significantly worse at the first visit with clinically active sacroiliitis versus the first visit without active sacroiliitis.
In this registry, there are more than 900 children with ERA or juvenile PsA. There was high biologic use in this population, especially in those with sacroiliitis. Further, there was equal sex representation in those children with sacroiliitis.
描述入组儿童关节炎和风湿病研究联盟(CARRA)注册研究的附着点相关关节炎(ERA)和少发性银屑病关节炎(PsA)患儿的特征。
鉴定所有 ERA 和少发性银屑病关节炎患儿。描述人口统计学特征、临床特征和治疗方法。比较有和无骶髂关节炎患儿。在有骶髂关节炎患儿中,比较首次出现临床活动性骶髂关节炎(72%患儿首先出现这种情况)和首次无临床活动性骶髂关节炎的情况。
共鉴定出 902 例 ERA 或少发性银屑病关节炎患儿。ERA 患儿的诊断年龄较大(10.8 岁 vs 8.2 岁;P<0.01),且更可能为男性(56% vs 38%;P<0.01)。57%的 ERA 患儿和 72%的少发性银屑病关节炎患儿有多发性关节炎累及。在接受检测的患儿中,ERA 患儿组 HLA-B27 阳性率为 38%,少发性银屑病关节炎患儿组为 12%。至少使用 1 种生物制剂的患儿在 ERA 患儿组占 72%,在少发性银屑病关节炎患儿组占 64%。28%的患儿有骶髂关节炎(临床和/或影像学诊断)(ERA 患儿中占 40%,少发性银屑病关节炎患儿中占 12%)。其中,54%为女性,36% HLA-B27 阳性,81%至少使用 1 种生物制剂。在有骶髂关节炎的患儿中,首次出现临床活动性骶髂关节炎时,医生总体疾病活动度评估、父母/患儿整体健康状况评估和临床幼年特发性关节炎疾病活动评分 10 的评分均显著高于首次无活动性骶髂关节炎时。
在本注册研究中,有 900 多名 ERA 或少发性银屑病关节炎患儿。该人群中生物制剂的使用较多,特别是在有骶髂关节炎的患儿中。此外,有骶髂关节炎的患儿中,男女性别比例相等。